AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33069120 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized Grip Strength (NGS, kg/kg)
Number of subjects: 24109
Study 33069120 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 24109
Study 32311398 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06700841 30 mg QD
Number of subjects: 212
Study 32311398 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06700841 60 mg QD
Number of subjects: 212
Study 32311398 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06700841 10 mg QD
Number of subjects: 212
Study 32311398 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06700841 30 mg QD (maintenance)
Number of subjects: 212
Study 32311398 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06700841 100 mg once weekly
Number of subjects: 212
Study 32311398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 35245081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 14)
Number of subjects: 30
Study 35245081 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 30
Study 32833483 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness combined with interoceptive exposure
Number of subjects: 0
Study 32833483 — intervention group
Group type: COMPARATOR
Intervention: Existing mindfulness interventions
Number of subjects: 0
Study 35852274 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mL buffered 1% lidocaine paracervical block
Number of subjects: 114
Study 35852274 — intervention group
Group type: COMPARATOR
Intervention: 40-mL buffered 0.5% lidocaine paracervical block
Number of subjects: 114
Study 35852274 — intervention group
Group type: COMPARATOR
Intervention: 40-mL buffered 0.5% lidocaine paracervical block (induced abortion)
Number of subjects: 114
Study 35852274 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mL buffered 1% lidocaine paracervical block (induced abortion)
Number of subjects: 114
Study 35852274 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mL buffered 1% lidocaine paracervical block (pain during administration)
Number of subjects: 114
Study 35852274 — intervention group
Group type: COMPARATOR
Intervention: 40-mL buffered 0.5% lidocaine paracervical block (pain during administration)
Number of subjects: 114
Study 35852274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (side effects)
Number of subjects: 114
Study 34859526 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigarettes offered by clinicians as a harm reduction strategy
Number of subjects: 21
Study 33974054 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD diagnosis
Number of subjects: 36309
Study 33974054 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD diagnosis with 5 criteria
Number of subjects: 36309
Study 33974054 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD diagnosis excluding self-injurious behavior
Number of subjects: 36309
Study 33974054 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-injurious behaviors
Number of subjects: 36309
Study 33974054 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic feelings of emptiness
Number of subjects: 36309
Study 32701901 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0
Study 32701901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36339149 — intervention group
Group type: EXPERIMENTAL
Intervention: HUA risk model
Number of subjects: 610
Study 33308998 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 0
Study 33308998 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33140287 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement (self-reports)
Number of subjects: 310
Study 33140287 — intervention group
Group type: EXPERIMENTAL
Intervention: Program-analytic indicator of dosage
Number of subjects: 310
Study 33140287 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational indicator
Number of subjects: 310
Study 35803368 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI) of propofol (effect-site, 2 μg.mL−1 plus 0.5 μg.mL−1 until unconsciousness and as necessary for agitation)
Number of subjects: 50
Study 35803368 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus of propofol (1 mg.kg−1 plus 0.5 mg.kg−1 every 5 minutes or as necessary)
Number of subjects: 50
Study 34656105 — intervention group
Group type: EXPERIMENTAL
Intervention: Male caregivers
Number of subjects: 1038
Study 34656105 — intervention group
Group type: EXPERIMENTAL
Intervention: Working caregivers
Number of subjects: 1038
Study 34656105 — intervention group
Group type: EXPERIMENTAL
Intervention: Female working caregivers
Number of subjects: 1038
Study 34656105 — intervention group
Group type: EXPERIMENTAL
Intervention: Male working caregivers
Number of subjects: 1038
Study 32480103 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinship Navigator Programs (Kinship Navigator Peer to Peer and Kinship Navigator with Innovations)
Number of subjects: 240
Study 32480103 — intervention group
Group type: COMPARATOR
Intervention: Usual Child Welfare
Number of subjects: 240
Study 35802637 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mobile-based perinatal mindfulness intervention (GMBPMI)
Number of subjects: 198
Study 35802637 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (Control)
Number of subjects: 198
Study 34626060 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen 5 mg/day (babytam)
Number of subjects: 500
Study 34626060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 32539675 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 321501
Study 32539675 — intervention group
Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 321501
Study 32539675 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 321501
Study 32539675 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 321501
Study 35805699 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuqinxi Qigong (WQ)
Number of subjects: 40
Study 35805699 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 40
Study 35805699 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 33724534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 33724534 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 215
Study 33724534 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline sGFAP concentrations (≥170 pg/ml)
Number of subjects: 215
Study 33724534 — intervention group
Group type: EXPERIMENTAL
Intervention: Attack severity
Number of subjects: 215
Study 33884442 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic medial meniscus replacement (MMR)
Number of subjects: 127
Study 33884442 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical care
Number of subjects: 127
Study 32900329 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg 12-hourly
Number of subjects: 48
Study 32900329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 32900329 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 48
Study 35657627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 114
Study 35657627 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 114
Study 36462539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cleansing with 1% povidone-iodine
Number of subjects: 608
Study 36462539 — intervention group
Group type: COMPARATOR
Intervention: Abdominal cleansing alone (Control)
Number of subjects: 608
Study 34160182 — intervention group
Group type: EXPERIMENTAL
Intervention: UHC plus a 30-day NP transitional care intervention
Number of subjects: 495
Study 34160182 — intervention group
Group type: EXPERIMENTAL
Intervention: UHC plus NP plus 60-day health coach intervention
Number of subjects: 495
Study 34160182 — intervention group
Group type: COMPARATOR
Intervention: Usual home care (UHC)
Number of subjects: 495
Study 32331049 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg SPN-812 (supratherapeutic dose)
Number of subjects: 100
Study 32331049 — intervention group
Group type: COMPARATOR
Intervention: 400 mg moxifloxacin (positive control)
Number of subjects: 100
Study 32331049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35000914 — intervention group
Group type: EXPERIMENTAL
Intervention: HEP+PWHi (High Intensity Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 50% duty cycle, 1.0 W/cm2)
Number of subjects: 25
Study 35000914 — intervention group
Group type: EXPERIMENTAL
Intervention: HEP+CWHi (Constant Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 100% duty cycle, 1.0 W/cm2)
Number of subjects: 25
Study 35000914 — intervention group
Group type: EXPERIMENTAL
Intervention: HEP+PWLi (Low Intensity Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 50% duty cycle, 0.5 W/cm2)
Number of subjects: 25
Study 35000914 — intervention group
Group type: EXPERIMENTAL
Intervention: HEP+CWLi (Low Intensity Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 100% duty cycle, 0.5 W/cm2)
Number of subjects: 25
Study 35000914 — intervention group
Group type: COMPARATOR
Intervention: HEP (Home Exercise Program, 5 times a week)
Number of subjects: 25
Study 32522156 — intervention group
Group type: EXPERIMENTAL
Intervention: LOR with epidural electrical stimulation (group E)
Number of subjects: 54
Study 32522156 — intervention group
Group type: COMPARATOR
Intervention: LOR (group L)
Number of subjects: 54
Study 36117007 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis as initial treatment
Number of subjects: 84
Study 36117007 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical intervention
Number of subjects: 84
Study 33632925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with ipilimumab and two cycles of platinum-doublet chemotherapy
Number of subjects: 719
Study 33258357 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 100
Study 33258357 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 100
Study 33258357 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 100
Study 34351285 — intervention group
Group type: EXPERIMENTAL
Intervention: Information feedback with social comparison reference points
Number of subjects: 0
Study 34351285 — intervention group
Group type: EXPERIMENTAL
Intervention: Information feedback with social comparison reference points (proximate norm)
Number of subjects: 0
Study 34351285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 0
Study 32223044 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose EPC (140 mg EPC and 130 mg OPC)
Number of subjects: 0
Study 32223044 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC (6 mg EPC and 130 mg OPC)
Number of subjects: 0
Study 32223044 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 32223044 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose EPC (70 mg EPC and 65 mg OPC)
Number of subjects: 0
Study 32096616 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Arm Training
Number of subjects: 20
Study 32096616 — intervention group
Group type: COMPARATOR
Intervention: Conventional Arm Training
Number of subjects: 20
Study 35679115 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone remote delivery method for health coaching
Number of subjects: 300
Study 35679115 — intervention group
Group type: COMPARATOR
Intervention: Videoconference remote delivery method for health coaching
Number of subjects: 300
Study 35848575 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TS)
Number of subjects: 1499
Study 35848575 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 1499
Study 35848575 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 1499
Study 35848575 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1499
Study 34341379 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein supplementation (Investigational Product, IP)
Number of subjects: 107
Study 34341379 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric normoproteic comparator (CP)
Number of subjects: 107
Study 34341379 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein supplementation (IP)
Number of subjects: 107
Study 32012064 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, computer-tailored intervention (Alerta Alcohol)
Number of subjects: 612
Study 32012064 — intervention group
Group type: COMPARATOR
Intervention: Control condition (baseline questionnaire only)
Number of subjects: 612
Study 33285097 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab plus platinum–etoposide
Number of subjects: 805
Study 33285097 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus platinum–etoposide
Number of subjects: 805
Study 33285097 — intervention group
Group type: COMPARATOR
Intervention: Platinum–etoposide
Number of subjects: 805
Study 32763628 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG activity during the composition task
Number of subjects: 0
Study 32763628 — intervention group
Group type: COMPARATOR
Intervention: EEG activity during the list task
Number of subjects: 0
Study 32763628 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-word composition task
Number of subjects: 0
Study 36343845 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid endoscopic submucosal dissection (H-ESD)
Number of subjects: 79
Study 36343845 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic submucosal dissection (C-ESD)
Number of subjects: 79
Study 33740892 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride
Number of subjects: 76
Study 33740892 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 76
Study 32950416 — intervention group
Group type: EXPERIMENTAL
Intervention: Litos drug-coated balloon (DCB)
Number of subjects: 105
Study 32950416 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 105
Study 34263700 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab added to DMARD combination
Number of subjects: 99
Study 34263700 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to DMARD combination
Number of subjects: 99
Study 33858020 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational‐volitional program (MoVo‐BnB) with 4 sessions led by physiotherapeutic and health pedagogic personnel
Number of subjects: 545
Study 33858020 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (Control Group)
Number of subjects: 545
Study 33469270 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic obeticholic acid (OCA) under fasting conditions
Number of subjects: 91
Study 33469270 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic obeticholic acid (OCA) under fed conditions
Number of subjects: 91
Study 33469270 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (OcalivaTM) under fasting conditions
Number of subjects: 91
Study 33469270 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (OcalivaTM) under fed conditions
Number of subjects: 91
Study 33469270 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake effect on pharmacokinetics
Number of subjects: 91
Study 32938477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg/day for 7 days, then 400 mg/day for 7 days)
Number of subjects: 27
Study 32938477 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent number of placebo tablets for 14 days)
Number of subjects: 27
Study 34255698 — intervention group
Group type: EXPERIMENTAL
Intervention: QuitPal-m app usage
Number of subjects: 181
Study 34255698 — intervention group
Group type: EXPERIMENTAL
Intervention: QuitPal-m app usage with counselor advice
Number of subjects: 181
Study 34255698 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived app helpfulness
Number of subjects: 181
Study 34255698 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 181
Study 34255698 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived barriers to app use
Number of subjects: 181
Study 34255698 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone technical problems
Number of subjects: 181
Study 34255698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes smoked per day at end of treatment
Number of subjects: 181
Study 34255698 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor app advice
Number of subjects: 181
Study 32468678 — intervention group
Group type: EXPERIMENTAL
Intervention: Not Scared of Sugar™ program
Number of subjects: 34
Study 35851584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sambucus williamsii var. coreana extract gargle
Number of subjects: 64
Study 35851584 — intervention group
Group type: COMPARATOR
Intervention: Saline solution gargle
Number of subjects: 64
Study 34325772 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 200 mg/kg PO (single dose)
Number of subjects: 21
Study 34325772 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 100 mg/kg PO (single dose)
Number of subjects: 21
Study 34325772 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 20 mg/kg PO q12h (repeated dosing)
Number of subjects: 21
Study 34325772 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 21
Study 36082667 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG+CEA
Number of subjects: 127
Study 36082667 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 127
Study 32347785 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 2146
Study 32347785 — intervention group
Group type: COMPARATOR
Intervention: Licensed trivalent influenza vaccines (TIVs)
Number of subjects: 2146
Study 35972777 — intervention group
Group type: EXPERIMENTAL
Intervention: RAW‐PA intervention (12-week intervention combining a wearable activity tracker with digital resources via a private Facebook group)
Number of subjects: 159
Study 35972777 — intervention group
Group type: EXPERIMENTAL
Intervention: RAW‐PA intervention
Number of subjects: 159
Study 35972777 — intervention group
Group type: COMPARATOR
Intervention: wait-list control group
Number of subjects: 159
Study 34488887 — intervention group
Group type: EXPERIMENTAL
Intervention: DDSS (Ada ? Your Health Guide)
Number of subjects: 102
Study 34488887 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 102
Study 34488887 — intervention group
Group type: EXPERIMENTAL
Intervention: DDSS
Number of subjects: 102
Study 34488887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 102
Study 34302544 — intervention group
Group type: EXPERIMENTAL
Intervention: Support-Based Spiritual Care Model nursing care
Number of subjects: 72
Study 34302544 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 32372651 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Number of subjects: 157
Study 32372651 — intervention group
Group type: COMPARATOR
Intervention: Non-specific knee taping
Number of subjects: 157
Study 35372380 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing-focused yoga intervention (BFY)
Number of subjects: 140
Study 35372380 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 140
Study 34503795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna group (SG)
Number of subjects: 36
Study 36320178 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine vaginal cleansing
Number of subjects: 0
Study 36320178 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic antibiotics
Number of subjects: 0
Study 34418588 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D hologram learning module combined with classroom lectures
Number of subjects: 90
Study 34418588 — intervention group
Group type: COMPARATOR
Intervention: Classroom lectures without 3D holograms
Number of subjects: 90
Study 33203141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (SAC/VAL)
Number of subjects: 0
Study 33203141 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 33203141 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab
Number of subjects: 0
Study 35266155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 3115
Study 35266155 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3115
Study 34028457 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice rehabilitation intervention group
Number of subjects: 20
Study 34028457 — intervention group
Group type: COMPARATOR
Intervention: Control group without rehabilitation
Number of subjects: 20
Study 35930585 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐PLB combined with rapid on‐site evaluation (ROSE)
Number of subjects: 108
Study 35930585 — intervention group
Group type: COMPARATOR
Intervention: No‐ROSE group
Number of subjects: 108
Study 34037351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethylmethylhydroxypyridine succinate (Neurox) 1 tablet (125 mg) 3 times a day for 4 weeks
Number of subjects: 129
Study 34037351 — intervention group
Group type: COMPARATOR
Intervention: Medical drugs (MD) not containing antihypoxants/antioxidants/nootropics
Number of subjects: 129
Study 32478879 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% microalgal product
Number of subjects: 33
Study 32478879 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% niacinamide (vitamin B3)
Number of subjects: 33
Study 32478879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 32478879 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light irradiation (4 × 60 J cm−2, 450 nm)
Number of subjects: 33
Study 35037963 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVEC with 40 mg MMC (once weekly for 6 weeks, then once monthly for 6 months)
Number of subjects: 50
Study 35037963 — intervention group
Group type: COMPARATOR
Intervention: BCG (once weekly for 6 weeks plus subsequent maintenance)
Number of subjects: 50